Maton P N, Murphy G M, Dowling R H
Gut. 1980 Dec;21(12):1082-6. doi: 10.1136/gut.21.12.1082.
This paper describes seven patients with radiolucent gallstones in functioning gallbladders who did not respond to chenodeoxycholic acid (CDCA). Despite large doses (greater than or equal to 19 mg CDCA/kg/day), CDCA-rich bile (CDCA conjugates 70-97% of total biliary bile acids) and greater than or equal to one year's treatment, their fasting duodenal bile remained supersaturated with cholesterol and their gallstones did not dissolve. Five patients came to cholecystectomy, gallstone analysis and liver biopsy for measurement of hepatic cholesterogenesis (HMGCoAR activity). In three who stopped CDCA before surgery, the mean HMGCoAR (pmol/mg microsomal protein/min) of 50.2 was higher than in our untreated gallstone controls (32.2 +/- SEM 2.0; P less than 0.05). Two patients who took CDCA until surgery had a mean HMGCoAR of 33.5--more than twice that in CDCA-treated gallstone controls. These findings suggest that non-response to CDCA may be related to high or unsuppressed hepatic cholesterogenesis. In one patient who did not respond to CDCA, treatment with 19 mg ursodeoxycholic acid/kg/day did desaturate his bile.
本文描述了7例胆囊功能正常但对鹅去氧胆酸(CDCA)无反应的X线透光性胆结石患者。尽管给予大剂量(≥19mg CDCA/kg/天)、富含CDCA的胆汁(CDCA结合物占总胆汁酸的70 - 97%)以及≥1年的治疗,但他们空腹十二指肠胆汁中的胆固醇仍处于过饱和状态,胆结石未溶解。5例患者接受了胆囊切除术、胆结石分析及肝活检以测量肝脏胆固醇生成(HMGCoAR活性)。在术前停用CDCA的3例患者中,平均HMGCoAR(pmol/mg微粒体蛋白/分钟)为50.2,高于未接受治疗的胆结石对照组(32.2±标准误2.0;P<0.05)。2例术前持续服用CDCA的患者平均HMGCoAR为33.5,是接受CDCA治疗的胆结石对照组的两倍多。这些发现提示,对CDCA无反应可能与肝脏胆固醇生成过高或未受抑制有关。在1例对CDCA无反应的患者中,给予19mg熊去氧胆酸/kg/天治疗后,其胆汁饱和度降低。